Cancer survival rates

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors

Retrieved on: 
Friday, April 8, 2022
Company, Private Securities Litigation Reform Act, Cancer, PSLRA, Sumathi Best Television Current Reporting Award, Ovary, Neck, SPEAR, ADAP, Cancer survival rates, AACR, Head, American Association, TCR, ADP, U.S. Securities and Exchange Commission, Association, American Association for Cancer Research, Nasdaq, Data, GLOBE, Science, HLA, Annual report, Engineering, Synovial sarcoma, Patient, Security (finance), Birth control, Medical imaging, Stomach

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a poster entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02–Eligible Patients”.

Key Points: 
  • This information confirms the potential of our MAGE-A4 franchise and our continued commitment to patients and clinicians.
  • The screening protocol prospectively evaluated HLA types and MAGE-A4 expression levels to determine eligibility for the Companys clinical trials with SPEAR T-cells targeting MAGE-A4 across a broad range of solid tumors.
  • To be eligible, patients are required to be HLA-A*02 positive1 and tumor samples need to meet protocol-defined MAGE-A4 expression levels2 .
  • Data were collected for screening in the Phase 1 trial of afami-cel (formerly ADP-A2M4; closed to enrollment) as well as the ongoing Phase1 SURPASS trial.

Oncologists Sound the Alarm on Drop in Cancer Screenings

Retrieved on: 
Wednesday, May 5, 2021
Medicine, Clinical medicine, Medical specialties, Cancer screening, Prostate cancer, Histopathology, Cancer, Breast cancer, Proton therapy, Screening, Cancer prevention, Cancer survival rates

Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.

Key Points: 
  • Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.
  • "These screenings could help detect cancer at its earliest, most treatable stage.
  • "\nDetecting cancer in the early stages, before it spreads, could make patients eligible for a non-surgical treatment option called proton therapy.\nProCure is New Jersey\'s most experienced proton therapy Center.
  • "That means fewer side effects and a lower risk of life-threatening medical issues.

Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer

Retrieved on: 
Friday, April 9, 2021
Cancer, Health, Clinical medicine, Infectious causes of cancer, Oncology, Histopathology, Prostate cancer, Lung cancer, Breast cancer, Colorectal cancer, Epidemiology of cancer, Cancer survival rates

According to the National Cancer Institute,roughly 1.8 million people were diagnosed with cancer in the United States in 2020.

Key Points: 
  • According to the National Cancer Institute,roughly 1.8 million people were diagnosed with cancer in the United States in 2020.
  • Overall, lung and bronchus cancer is the second most common cancer diagnosis with an estimated 228,820 new cases.
  • Prostate cancer is the leading cancer diagnosis among men and the third most common diagnosis overall with 191,930 expected cases.
  • While the focus is initially on improving the diagnosis of breast cancer and colon cancer using this method, the potential applies to all cancers.

Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer

Retrieved on: 
Friday, April 9, 2021
Cancer, Health, Clinical medicine, Infectious causes of cancer, Oncology, Histopathology, Prostate cancer, Lung cancer, Breast cancer, Colorectal cancer, Epidemiology of cancer, Cancer survival rates

According to the National Cancer Institute,roughly 1.8 million people were diagnosed with cancer in the United States in 2020.

Key Points: 
  • According to the National Cancer Institute,roughly 1.8 million people were diagnosed with cancer in the United States in 2020.
  • Overall, lung and bronchus cancer is the second most common cancer diagnosis with an estimated 228,820 new cases.
  • Prostate cancer is the leading cancer diagnosis among men and the third most common diagnosis overall with 191,930 expected cases.
  • While the focus is initially on improving the diagnosis of breast cancer and colon cancer using this method, the potential applies to all cancers.

Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis

Retrieved on: 
Tuesday, April 6, 2021
Oncology, Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Oncology, Cancer, Medical specialties, Health, Metástasis, Treatment of cancer, Prostate cancer, Metastatic breast cancer, Cancer survival rates

In the U.S. alone, more than 350,000 people a year are diagnosed with metastatic cancer.

Key Points: 
  • In the U.S. alone, more than 350,000 people a year are diagnosed with metastatic cancer.
  • Less than a third respond to targeted or immuno-therapies, making metastasis one of the most pressing unsolved challenges in cancer.
  • Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment.
  • Based in West Harlem, N.Y., Volastra is committed to improving outcomes for people living with cancer.

Breast Cancer Alliance Celebrates 25th Anniversary With Renewed Commitment to Healthier Future

Retrieved on: 
Tuesday, March 23, 2021
Oncology, Health, Clinical medicine, Breast cancer, Cancer survival rates, Cancer, Breast cancer awareness

While breast cancer survival rates have gone from 75 to 90 percent since the charity first began, BCA is pledging to help close the gap even further this decade.

Key Points: 
  • While breast cancer survival rates have gone from 75 to 90 percent since the charity first began, BCA is pledging to help close the gap even further this decade.
  • "By 2030, we want to approach 100% breast cancer survival rate and we're dedicating ourselves to that ambitious goal."
  • "Our milestone 25th anniversary is not an end point, but a commemoration, an important reminder of our legacy and commitment to a brighter, healthier future with 100 percent survival within reach."
  • The mission of Breast Cancer Alliance is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure.

Single-Dose Radiation Therapy Can Counteract Serious Breast Cancer Treatment Compliance Issues During Pandemic

Retrieved on: 
Wednesday, December 16, 2020
Medicine, Clinical medicine, Medical specialties, Intraoperative radiation therapy, Targeted intra-operative radiotherapy, Medical physics, Breast surgery, Lumpectomy, Radiation therapy, Breast cancer, Intraoperative electron radiation therapy, Cancer survival rates

This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Key Points: 
  • This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.
  • IORT is a single treatment which takes the place of external beam radiation therapy (EBRT) done at the time of the lumpectomy.
  • The TARGIT-IORT treatment administers the radiation dose from inside the breast at the time of surgery, precisely where it is needed.
  • The clinical trial demonstrated equal breast cancer recurrence rates and equal cancer survival rates among recipients of targeted IORT during lumpectomy compared to those receiving multiple weeks of whole breast radiation after lumpectomy.

New Study Finds COVID-19 Substantially Reduced Cancer Screenings, Diagnosis, and Treatments in 2020

Retrieved on: 
Wednesday, October 21, 2020
RTT, Cancer, Clinical medicine, Medicine, Prostate cancer, Oncology, Breast cancer, Radiation therapy, Chemotherapy, Book:Cancer, Cancer survival rates

WASHINGTON, Oct. 21, 2020 /PRNewswire/ --Breast, colon, prostate, and lung cancers did not stop for COVID-19 in 2020, but screenings and treatments did.

Key Points: 
  • WASHINGTON, Oct. 21, 2020 /PRNewswire/ --Breast, colon, prostate, and lung cancers did not stop for COVID-19 in 2020, but screenings and treatments did.
  • The study, conducted for the non-profit Community Oncology Alliance (COA) by Avalere Health , examined the billing frequencies from March-July 2020 for common cancer procedures, including screenings, infusion therapies such as chemotherapy, surgeries, and radiation therapy.
  • It found significant reductions in breast (-85%), colon (-75%), prostate (-74%), and lung cancer (-56%) screenings at the first peak of the pandemic in April 2020, compared with April 2019.
  • The mission of COA is to ensure that cancer patients receive quality, affordable, and accessible cancer care in their own communities.

Transpara® Breast Care launch helps drive the worldwide adoption of AI to assist in the fight against breast cancer

Retrieved on: 
Wednesday, October 21, 2020
Clinical medicine, Medicine, Cancer screening, Health, RTT, Breast imaging, Mammography, Projectional radiography, Breast cancer, Cancer survival rates, Cancer, Risk factors for breast cancer

Nicki Bryan, Vice President of Sales for ScreenPoint Medical in the United States, said she is delighted to see this rapid adoption of Transpara.

Key Points: 
  • Nicki Bryan, Vice President of Sales for ScreenPoint Medical in the United States, said she is delighted to see this rapid adoption of Transpara.
  • "We want to make a real difference in the lives of families by reducing the impact of breast cancer and improving survival rates.
  • We started this company to help improve breast cancer survival and we work tirelessly to ensure that breast cancer can be found faster and earlier.
  • Transpara is an AI solution for breast cancer screening, that uses deep learning algorithms to automatically detect lesions suspicious for breast cancer in 2D and 3D mammograms.

The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025

Retrieved on: 
Wednesday, October 21, 2020
Clinical medicine, Medicine, RTT, Antineoplastic drugs, Prostate cancer, Cancer treatments, Breast cancer, Cancer, Chemotherapy, Targeted therapy, Cancer survival rates, Oncology

Number of Cancer Drugs in Development for the Years 2006, 2009,

Key Points: 
  • Number of Cancer Drugs in Development for the Years 2006, 2009,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    Number of New Cancer Cases in Canada: 2019
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    Number of New Cancer Cases Diagnosed (in Thousands) in the UK:
    by Geographic Region - France, Germany, Italy, UK, Spain,
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    Therapies by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    Therapies by Cancer Type - Blood Cancer, Breast Cancer,
    Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    by Treatment Type - Chemotherapy, Targeted Therapy,
    and Other Treatment Types for the Years 2009, 2020 & 2025
    by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.